FDA Breakthrough Designations are significant for pharmaceutical companies as they can lead to faster development and review of drugs, which in turn can result in quicker market access and revenue generation. For Novartis, this designation for Scemblix could enhance its competitive edge in the market, potentially leading to positive investor sentiment and an uptick in stock price in the short term.